NTRK2 and neoplasm: The first prerequisite for clinical progress is molecular stratification that distinguishes tumours driven by ligand-dependent NGF-TrkA, BDNF-TrkB or GDNF–RET loops from those harbouring activating rearrangements or kinase-domain point mutations.